Corrigendum to Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014 [Intern Med J 44, (2015), 1350-1363], doi:10.1111/imj.12599;Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

Internal Medicine Journal

Volumn 44, Issue 12, 2014, Pages 1350-1363

  Cooley, L ^a   Dendle, C ^b,c   Wolf, J ^d,e   Teh, B W ^f   Chen, S C ^g,h,i   Boutlis, C ^j,k   Thursky, K A ^f,l  

^a ROYAL HOBART HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d St Jude Children's Research   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g Pathology West ICPMR Westmead   (Australia)

^h WESTMEAD HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j WOLLONGONG HOSPITAL   (Australia)

^k UNIVERSITY OF WOLLONGONG   (Australia)

^l PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

more..

Author keywords

Haematological malignancy; Pneumocystis carinii; Pneumocystis jirovecii; Prophylaxis; Solid organ tumour; Treatment

Indexed keywords

ATOVAQUONE; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; PENTAMIDINE;

ANTIBIOTIC PROPHYLAXIS; CANCER PATIENT; CHEMOPROPHYLAXIS; DRUG TREATMENT FAILURE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; ORGAN TRANSPLANTATION; PATIENT RISK; PNEUMOCYSTIS JIROVECII PNEUMONIA; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; REVIEW; SOLID TUMOR; TREATMENT DURATION; TREATMENT FAILURE; COMPLICATION; CONSENSUS; DRUG ADMINISTRATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MICROBIOLOGY; NEOPLASM; OPPORTUNISTIC INFECTIONS; PATHOGENICITY; PNEUMOCYSTIS JIROVECI; PNEUMONIA, PNEUMOCYSTIS;

ADRENAL CORTEX HORMONES; ANTIBIOTIC PROPHYLAXIS; CONSENSUS; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOCOMPROMISED HOST; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PRACTICE GUIDELINES AS TOPIC; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84914812931     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12708     Document Type: Erratum

References (131)

1. Nuesch R, Bellini C, Zimmerli W. Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients. Clin Infect Dis 1999; 29: 1519-1523.
2. Matsumura Y, Shindo Y, Iinuma Y, Yamamoto M, Shirano M, Matsushima A etal. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011; 11: 76.
3. Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P etal. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 117: 379-386.
4. Roblot F, Imbert S, Godet C, Kauffmann C, Ragot S, Le Moal G etal. Risk factors analysis for Pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia. Scand J Infect Dis 2004; 36: 848-854.
5. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000; 118: 704-711.
6. Limper AH. Alveolar macrophage and glycoprotein responses to Pneumocystis carinii. Semin Respir Infect 1998; 13: 339-347.
7. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992; 267: 832-837.
8. Cregan P, Yamamoto A, Lum A, VanDerHeide T, MacDonald M, Pulliam L. Comparison of four methods for rapid detection of Pneumocystis carinii in respiratory specimens. J Clin Microbiol 1990; 28: 2432-2436.
9. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140: 1204-1209.
10. Robberts FJ, Liebowitz LD, Chalkley LJ. Polymerase chain reaction detection of Pneumocystis jiroveci: evaluation of 9 assays. Diagn Microbiol Infect Dis 2007; 58: 385-392.
11. Lu Y, Ling G, Qiang C, Ming Q, Wu C, Wang K etal. PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol 2011; 49: 4361-4363.
12. Fan LC, Lu HW, Cheng KB, Li HP, Xu JF. Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review. PLoS ONE 2013; 8: e73099.
13. Huggett JF, Taylor MS, Kocjan G, Evans HE, Morris-Jones S, Gant V etal. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax 2008; 63: 154-159.
14. Matsumura Y, Ito Y, Iinuma Y, Yasuma K, Yamamoto M, Matsushima A etal. Quantitative real-time PCR and the (1- > 3)-beta-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. Clin Microbiol Infect 2012; 18: 591-597.
15. Botterel F, Cabaret O, Foulet F, Cordonnier C, Costa JM, Bretagne S. Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients. J Clin Microbiol 2012; 50: 227-231.
16. Muhlethaler K, Bogli-Stuber K, Wasmer S, von Garnier C, Dumont P, Rauch A etal. Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J 2012; 39: 971-978.
17. Alanio A, Desoubeaux G, Sarfati C, Hamane S, Bergeron A, Azoulay E etal. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 2011; 17: 1531-1537.
18. Maillet M, Maubon D, Brion JP, Francois P, Molina L, Stahl JP etal. Pneumocystis jirovecii (Pj) quantitative PCR to differentiate Pj pneumonia from Pj colonization in immunocompromised patients. Eur J Clin Microbiol Infect Dis 2013.
19. Damiani C, Le Gal S, Da Costa C. Virmaux M, Nevez G, Totet A. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1- > 3)-beta-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol 2013; 51: 3380-3388.
20. Teh BW, Azzato FA, Lingaratnam SM, Thursky KA, Slavin MA, Worth LJ. Molecular diagnosis of Pneumocystis jirovecii in patients with malignancy: clinical significance of quantitative polymerase chain reaction. Med Mycol 2014; 52(4): 427-432.
21. Larsen HH, Masur H, Kovacs JA, Gill VJ, Silcott VA, Kogulan P etal. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol 2002; 40: 490-494.
22. Vogel MN, Vatlach M, Weissgerber P, Goeppert B, Claussen CD, Hetzel J etal. HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol 2012; 81: 1315-1320.
23. Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol 2012; 198: W555-561.
24. Tasaka S, Tokuda H, Sakai F, Fujii T, Tateda K, Johkoh T etal. Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med 2010; 49: 273-281.
25. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 2007; 13: 1-7.
26. Reid AB, Chen SC, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 2011; 24: 534-544.
27. Haeusler GM, Slavin MA, Seymour JF, Lingaratnam S, Teh BW, Tam CS etal. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. Eur J Haematol 2013; 91: 157-163.
28. Nakazato T, Mihara A, Sanada Y, Suzuki K, Aisa Y, Iwabuchi M etal. Pneumocystis jiroveci pneumonia detected by FDG-PET. Ann Hematol 2010; 89: 839-840.
29. Hughes WT, Kuhn S, Chaudhary S, Feldman S, Verzosa M, Aur RJ etal. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977; 297: 1419-1426.
30. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82: 1052-1059.
31. Ross LE, Hall IJ African American primary care physicians' prostate cancer screening practices. J Prim Care Community Health 2014; 5: 36-43.
32. Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M, Infectious Diseases Working Party (AGIHO) etal. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013; 92: 433-442.
33. Peters SG, Prakash UB. Pneumocystis carinii pneumonia. Review of 53 cases. Am J Med 1987; 82: 73-78.
34. Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 1995; 155: 2436-2441.
35. Wondergem MJ, Grunberg K, Wittgen BP, Sonneveld P, Zweegman S. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment. Histopathology 2009; 54: 631-633.
36. Shimoma J, Yanagisawa K, Saito B, Kawakami K, Nakamaki T, Tomoyasu S. A case of IgG kappa-type multiple myeloma complicated with carinii pneumonia following thalidomide administration. Jpn J Antibiot 2006; 59: 410-412.
37. McKenzie RS, Glenn LD, Goldsmith JC. Pneumocystis carinii pneumonia complicating multiple myeloma. Chest 1991; 99: 656-659.
38. Hardak E, Oren I, Dann EJ, Yigla M, Faibish T, Rowe JM etal. The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience. Acta Haematol 2012; 127: 110-114.
39. Chang H, Yeh HC, Su YC, Lee MH. Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab. J Chin Med Assoc 2008; 71: 579-582.
40. Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 2008; 80: 275-276.
41. Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW etal. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 2011; 90: 1145-1151.
42. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010; 51: 797-801.
43. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007; 92: 139-140.
44. Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM etal. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Korean J Intern Med 2010; 25: 86-92.
45. Kim T, Choi SH, Kim SH, Jeong JY, Woo JH, Kim YS etal. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy. Ann Hematol 2013; 92: 231-238.
46. Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K etal. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 2008; 87: 393-397.
47. Garcia-Noblejas A, Velasco A, Garcia-Leon N, Cananta-Ortiz J, Steegmann JL. Pneumocystis jirovecii pneumonia as first manifestation of late relapse angioimmunoblastic T-cell lymphoma. Leuk Res 2011; 35: e143-144.
48. Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975; 36: 2004-2009.
49. De Castro N, Neuville S, Sarfati C, Ribaud P, Derouin F, Gluckman E etal. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005; 36: 879-883.
50. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev Infect Dis 1982; 4: 1119-1132.
51. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71: 5-13.
52. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006; 132: 3-12.
53. Tadmor T, McLaughlin P, Polliack A. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? Leuk Lymphoma 2010; 51: 737-738.
54. Kalin M, Kristinsson SY, Cherif H, Lebbad M, Bjorkholm M. Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients. Ann Hematol 2010; 89: 523-525.
55. Lingaratnam SM, Slavin MA, Thursky KA, Teh BW, Haeusler GM, Seymour JF etal. Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian centre and recommendations for targeted prophylaxis. Leuk Lymphoma 2014; Epub ahead of print.
56. Hashimoto K, Kobayashi Y, Asakura Y, Mori M, Azuma T, Maruyama D etal. Pneumocystis jiroveci pneumonia in relation to CD4 + lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma 2010; 51: 1816-1821.
57. Seymour JF. Concerns regarding data supporting recent Pneumocystis jirovecii prophylaxis guidelines. Ann Hematol 2013; 92: 1569-1570.
58. Katsuya H, Suzumiya J, Sasaki H, Ishitsuka K, Shibata T, Takamatsu Y etal. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 1818-1823.
59. Worth LJ, Dooley MJ, Seymour JF, Mileshkin L, Slavin MA, Thursky KA. An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 2005; 92: 867-872.
60. Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M etal. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002; 21: 523-531.
61. Roblot F, Le Moal G, Kauffmann-Lacroix C, Bastides F, Boutoille D, Verdon R etal. Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment. Scand J Infect Dis 2014; 46: 210-214.
62. Sepkowitz KA. Pneumocystis carinii pneumonia among patients with neoplastic disease. Semin Respir Infect 1992; 7: 114-121.
63. Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 2012; 18: 793-806.
64. American Academy of Paediatrics. Red book: 2012 Report of the Committee on Infectious Diseases. 29th edn. Pickering L, ed. Elk Grove Village, IL: American Academy of Paediatrics; 2012.
65. Henson JW, Jalaj JK, Walker RW, Stover DE, Fels AO. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 1991; 48: 406-409.
66. Slivka A, Wen PY, Shea WM, Loeffler JS. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 1993; 94: 216-219.
67. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E etal. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 2006; 95: 1155-1160.
68. Balana C, Lopez-Pousa A, Berrocal A, Yaya-Tur R, Herrero A, Garcia JL etal. Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). J Neurooncol 2004; 70: 359-369.
69. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P etal. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-1382.
70. De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, van Herpen CM. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Crit Rev Oncol Hematol 2013; 85: 373-382.
71. Kim SY, Dabb AA, Glenn DJ, Snyder KM, Chuk MK, Loeb DM. Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatr Blood Cancer 2008; 50: 779-783.
72. Sibanda EL, Weller IV, Hakim JG, Cowan FM. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin Infect Dis 2011; 52: 1184-1194.
73. Rossi MR, Banfi P, Cappuccilli M, Conter V, de Poli D, Piacentini G etal. Prospective randomized comparison of two prophylactic regimens with trimethoprim-sulfamethoxazole in leukemic children: a two year study. Eur J Cancer Clin Oncol 1987; 23: 1679-1682.
74. Caselli D, Petris MG, Rondelli R, Carraro F, Colombini A, Muggeo P etal. Single-day trimethoprim/sulfamethoxazole prophylaxis for pneumocystis pneumonia in children with cancer. J Pediatr 2013; 164(2): 389-392.e1
75. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987; 316: 1627-1632.
76. Muto T, Takeuchi M, Kawaguchi T, Tanaka S, Tsukamoto S, Sakai S etal. Low-dose trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 1573-1575.
77. Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999; 29: 1467-1471.
78. Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 2000; 6: 35-43.
79. Imrie KR, Prince HM, Couture F, Brandwein JM, Keating A. Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole. Bone Marrow Transplant 1995; 15: 267-270.
80. Fontanet A, Chalandon Y, Roosnek E, Mohty B, Passweg JR. Cotrimoxazole myelotoxicity in hematopoietic SCT recipients: time for reappraisal. Bone Marrow Transplant 2011; 46: 1272-1273.
81. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH etal. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12: 1667-1672.
82. Lane BR, Ast JC, Hossler PA, Mindell DP, Bartlett MS, Smith JW etal. Dihydropteroate synthase polymorphisms in Pneumocystis carinii. J Infect Dis 1997; 175: 482-485.
83. Dini L, Du Plessis M, Frean J, Fernandez V. High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneumonia in South Africa. J Clin Microbiol 2010; 48: 2016-2021.
84. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999; 354: 1347-1351.
85. Kazanjian P, Armstrong W, Hossler PA, Burman W, Richardson J, Lee CH etal. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 2000; 182: 551-557.
86. Navin TR, Beard CB, Huang L, del Rio C, Lee S, Pieniazek NJ etal. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study. Lancet 2001; 358: 545-549.
87. Voeller D, Kovacs J, Andrawis V, Chu E, Masur H, Allegra C. Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone). J Infect Dis 1994; 169: 456-459.
88. Cruciani M, Gatti G, Mengoli C, Cazzadori A, Lazzarini L, Miletich F etal. Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1997; 41: 1077-1081.
89. Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 1998; 27: 191-204.
90. Slavin MA, Hoy JF, Stewart K, Pettinger MB, Lucas CR, Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992; 6: 1169-1174.
91. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007; (3): CD 005590.
92. DeMasi JM, Cox JA, Leonard D, Koh AY, Aquino VM. Intravenous pentamidine is safe and effective as primary pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation. Pediatr Infect Dis J 2013; 32: 933-936.
93. Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 897-902.
94. Therapeutic Guidelines: Antibiotic, Version 15. Melbourne, Australia: Therapeutic Guidelines Limited; 2014.
95. Safrin S, Finkelstein DM, Feinberg J, Frame P, Simpson G, Wu A etal. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996; 124: 792-802.
96. Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P etal. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993; 328: 1521-1527.
97. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med 1992; 327: 1853-1860.
98. Corticosteroid therapy for AIDS-associated PCP. Am Fam Physician 1990; 42: 1672-1675.
99. Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C etal. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990; 323: 1451-1457.
100. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med 1990; 323: 1444-1450.
101. Montaner JS, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 113: 14-20.
102. El Sadr W, Simberkoff MS. Survival and prognostic factors in severe Pneumocystis carinii pneumonia requiring mechanical ventilation. Am Rev Respir Dis 1988; 137: 1264-1267.
103. Moon SM, Kim T, Sung H, Kim MN, Kim SH, Choi SH etal. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 2011; 55: 4613-4618.
104. Delclaux C, Zahar JR, Amraoui G, Leleu G, Lebargy F, Brochard L etal. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis 1999; 29: 670-672.
105. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113: 1215-1224.
106. Klein NC, Duncanson FP, Lenox TH, Forszpaniak C, Sherer CB, Quentzel H etal. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS 1992; 6: 301-305.
107. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 1988; 109: 280-287.
108. Helweg-Larsen J, Benfield T, Atzori C, Miller RF. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother 2009; 64: 1282-1290.
109. Conte JE Jr, Chernoff D, Feigal DW Jr, Joseph P, McDonald C, Golden JA. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann Intern Med 1990; 113: 203-209.
110. Toma E, Thorne A, Singer J, Raboud J, Lemieux C, Trottier S etal. Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group. Clin Infect Dis 1998; 27: 524-530.
111. Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G etal. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323: 776-782.
112. Kottom TJ, Limper AH. Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta -1, 3-glucan deposition. J Biol Chem 2000; 275: 40628-40634.
113. Mu XD, Que CL, He B, Wang GF, Li HC. Caspofungin in salvage treatment of severe pneumocystis pneumonia: case report and literature review. Chin Med J (Engl) 2009; 122: 996-999.
114. Kim T, Hong HL, Lee YM, Sung H, Kim SH, Choi SH etal. Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review. Scand J Infect Dis 2013; 45: 484-488.
115. Kamboj M, Weinstock D, Sepkowitz KA. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis 2006; 43: e92-94.
116. Beltz K, Kramm CM, Laws HJ, Schroten H, Wessalowski R, Gobel U. Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia. Klin Padiatr 2006; 218: 177-179.
117. Ceballos ME, Ortega M, Andresen M, Wozniak A, Garcia P, Balcells ME. Successful treatment with echinocandin in an HIV-infected individual failing first-line therapy for Pneumocystis jirovecii pneumonia. AIDS 2011; 25: 2192-2193.
118. Schmoldt S, Schuhegger R, Wendler T, Huber I, Sollner H, Hogardt M etal. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008; 46: 966-971.
119. Phipps LM, Chen SC, Kable K, Halliday CL, Firacative C, Meyer W etal. Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients. Transplantation 2011; 92: 1327-1334.
120. de Boer MG, de Fijter JW, Kroon FP. Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients: a systematic review. Med Mycol 2011; 49: 673-680.
121. Bensousan T, Garo B, Islam S, Bourbigot B, Cledes J, Garre M. Possible transfer of Pneumocystis carinii between kidney transplant recipients. Lancet 1990; 336: 1066-1067.
122. Damiani C, Choukri F, Le Gal S, Menotti J, Sarfati C, Nevez G etal. Possible nosocomial transmission of Pneumocystis jirovecii. Emerg Infect Dis 2012; 18: 877-878.
123. Choukri F, Menotti J, Sarfati C, Lucet JC, Nevez G, Garin YJ etal. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010; 51: 259-265.
124. Bartlett MS, Vermund SH, Jacobs R, Durant PJ, Shaw MM, Smith JW etal. Detection of Pneumocystis carinii DNA in air samples: likely environmental risk to susceptible persons. J Clin Microbiol 1997; 35: 2511-2513.
125. Le Gal S, Damiani C, Rouille A, Grall A, Treguer L, Virmaux M etal. A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis 2012; 54: e62-71.
126. Vargas SL, Ponce CA, Gigliotti F, Ulloa AV, Prieto S, Munoz MP etal. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 2000; 38: 1536-1538.
127. Medrano FJ, Montes-Cano M, Conde M, de la Horra C, Respaldiza N, Gasch A etal. Pneumocystis jirovecii in general population. Emerg Infect Dis 2005; 11: 245-250.
128. Chabe M, Dei-Cas E, Creusy C, Fleurisse L, Respaldiza N, Camus D etal. Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and rt-PCR data demonstrate active replication. Eur J Clin Microbiol Infect Dis 2004; 23: 89-97.
129. Rostved AA, Sassi M, Kurtzhals JA, Sorensen SS, Rasmussen A, Ross C etal. Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii. Transplantation 2013; 96: 834-842.
130. Gianella S, Haeberli L, Joos B, Ledergerber B, Wuthrich RP, Weber R etal. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl Infect Dis 2010; 12: 1-10.
131. Nankivell BJ, Firacative C, Kable K, Chen SC, Meyer W. Molecular epidemiology linking multihospital clusters of opportunistic Pneumocystis jirovecii pneumonia. Clin Infect Dis 2013; 57: 1058-1059.